Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and Hb variants for the detection of Heamoglobinapothies. It also develops, manufactures, and distributes products in the immunofluorescence, enzyme-linked immunosorbent, western blot, and cytotoxicity assay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for detecting liver and kidney diseases, as well as haemolytic anaemia. In addition, the company offers Uni-Gold HIV, a POC diagnostic test, which is carried out in the presence of the patient to diagnose the presence of HIV antibodies. Further, it provides emergency medicine diagnostic tests; and sells raw materials to the life sciences industry and research institutes. Additionally, it offers Uni-Gold S. pneumoniae, Uni-Gold Legionella, Uni-Gold C. difficile, and Uni-Gold Syphilis products. The company sells its products through its direct sales force in the United States; and a network of independent distributors and strategic partners internationally. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.
Trinity Biotech plans to cut spending after withdrawal of device application with FDA Trinity Biotech plc TRIB, -48.10% shares dropped as much as 50% in premarket trade Tuesday after the company said it withdrew its device application with the Food and Drug Administration on the regulator's advice. As part of the withdrawal, Trinity also said it would reduce spending by nearly 85%, to $1.5 million from $9 million a year, and that it would close a Swedish facility, eliminating 40 jobs. The Dublin-based developer of diagnostic products said that while it was confident in the Meritas Troponin-I Test and Meritas Point-of-Care Analyzer, it was not sure the point-of-care device could meet the FDA's standard requiring equivalent performance to the most recently cleared lab-based Troponin product. Trinity said it would spend the next nine to 12 months determining the best move forward for the platform, and would move the technology from the Swedish facility to an existing one in Ireland
